174 results on '"Kimby, Eva"'
Search Results
2. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
- Author
-
Buske, Christian, Dimopoulos, Meletios A., Grunenberg, Alexander, Kastritis, Efstathios, Tomowiak, Cecile, Mahé, Béatrice, Troussard, Xavier, Hajek, Roman, Viardot, Andreas, Tournilhac, Olivier, Aurran, Therese, Lepretre, Stephane, Zerazhi, Hacene, Hivert, Benedicte, Leblond, Veronique, de Guibert, Sophie, Brandefors, Lena, Garcia-Sanz, Ramon, Gomes da Silva, Maria, and Kimby, Eva
- Published
- 2023
- Full Text
- View/download PDF
3. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
- Author
-
Los-de Vries, G. Tjitske, Stevens, Wendy B. C., van Dijk, Erik, Langois-Jacques, Carole, Clear, Andrew J., Stathi, Phylicia, Roemer, Margaretha G. M., Mendeville, Matias, Hijmering, Nathalie J., Sander, Birgitta, Rosenwald, Andreas, Calaminici, Maria, Hoster, Eva, Hiddemann, Wolfgang, Gaulard, Philippe, Salles, Gilles, Horn, Heike, Klapper, Wolfram, Xerri, Luc, Burton, Catherine, Tooze, Reuben M., Smith, Alexandra G., Buske, Christian, Scott, David W., Natkunam, Yasodha, Advani, Ranjana, Sehn, Laurie H., Raemaekers, John, Gribben, John, Kimby, Eva, Kersten, Marie José, Maucort-Boulch, Delphine, Ylstra, Bauke, and de Jong, Daphne
- Abstract
Although the genomic and immune microenvironmental landscape of follicular lymphoma (FL) has been extensively investigated, little is known about the potential biological differences between stage I and stage III/IV disease. Using next-generation sequencing and immunohistochemistry, 82 FL nodal stage I cases were analyzed and compared with 139 FL stage III/IV nodal cases. Many similarities in mutations, chromosomal copy number aberrations, and microenvironmental cell populations were detected. However, there were also significant differences in microenvironmental and genomic features. CD8+ T cells (P = .02) and STAT6 mutations (false discovery rate [FDR] <0.001) were more frequent in stage I FL. In contrast, programmed cell death protein 1–positive T cells, CD68+/CD163+ macrophages (P < .001), BCL2 translocation (BCL2trl+) (P < .0001), and KMT2D (FDR = 0.003) and CREBBP (FDR = 0.04) mutations were found more frequently in stage III/IV FL. Using clustering, we identified 3 clusters within stage I, and 2 clusters within stage III/IV. The BLC2trl+ stage I cluster was comparable to the BCL2trl+ cluster in stage III/IV. The two BCL2trl– stage I clusters were unique for stage I. One was enriched for CREBBP (95%) and STAT6 (64%) mutations, without BLC6 translocation (BCL6trl), whereas the BCL2trl– stage III/IV cluster contained BCL6trl (64%) with fewer CREBBP (45%) and STAT6 (9%) mutations. The other BCL2trl– stage I cluster was relatively heterogeneous with more copy number aberrations and linker histone mutations. This exploratory study shows that stage I FL is genetically heterogeneous with different underlying oncogenic pathways. Stage I FL BCL2trl– is likely STAT6 driven, whereas BCL2trl– stage III/IV appears to be more BCL6trl driven.
- Published
- 2022
- Full Text
- View/download PDF
4. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
- Author
-
Los-de Vries, G. Tjitske, Stevens, Wendy B.C., van Dijk, Erik, Langois-Jacques, Carole, Clear, Andrew J., Stathi, Phylicia, Roemer, Margaretha G.M., Mendeville, Matias, Hijmering, Nathalie J., Sander, Birgitta, Rosenwald, Andreas, Calaminici, Maria, Hoster, Eva, Hiddemann, Wolfgang, Gaulard, Philippe, Salles, Gilles, Horn, Heike, Klapper, Wolfram, Xerri, Luc, Burton, Catherine, Tooze, Reuben M., Smith, Alexandra G., Buske, Christian, Scott, David W., Natkunam, Yasodha, Advani, Ranjana, Sehn, Laurie H., Raemaekers, John, Gribben, John, Kimby, Eva, Kersten, Marie José, Maucort-Boulch, Delphine, Ylstra, Bauke, and de Jong, Daphne
- Abstract
Although the genomic and immune microenvironmental landscape of follicular lymphoma (FL) has been extensively investigated, little is known about the potential biological differences between stage I and stage III/IV disease. Using next-generation sequencing and immunohistochemistry, 82 FL nodal stage I cases were analyzed and compared with 139 FL stage III/IV nodal cases. Many similarities in mutations, chromosomal copy number aberrations, and microenvironmental cell populations were detected. However, there were also significant differences in microenvironmental and genomic features. CD8+T cells (P= .02) and STAT6mutations (false discovery rate [FDR] <0.001) were more frequent in stage I FL. In contrast, programmed cell death protein 1–positive T cells, CD68+/CD163+macrophages (P< .001), BCL2translocation (BCL2trl+) (P< .0001), and KMT2D(FDR = 0.003) and CREBBP(FDR = 0.04) mutations were found more frequently in stage III/IV FL. Using clustering, we identified 3 clusters within stage I, and 2 clusters within stage III/IV. The BLC2trl+stage I cluster was comparable to the BCL2trl+cluster in stage III/IV. The two BCL2trl–stage I clusters were unique for stage I. One was enriched for CREBBP(95%) and STAT6(64%) mutations, without BLC6translocation (BCL6trl), whereas the BCL2trl–stage III/IV cluster contained BCL6trl (64%) with fewer CREBBP(45%) and STAT6(9%) mutations. The other BCL2trl–stage I cluster was relatively heterogeneous with more copy number aberrations and linker histone mutations. This exploratory study shows that stage I FL is genetically heterogeneous with different underlying oncogenic pathways. Stage I FL BCL2trl–is likely STAT6 driven, whereas BCL2trl–stage III/IV appears to be more BCL6trl driven.
- Published
- 2022
- Full Text
- View/download PDF
5. Distinct clinical and genetic features of hepatitis B virus–associated follicular lymphoma in Chinese patients
- Author
-
Ren, Weicheng, Wang, Xianhuo, Yang, Mingyu, Wan, Hui, Li, Xiaobo, Ye, Xiaofei, Meng, Bing, Li, Wei, Yu, Jingwei, Lei, Mengyue, Xie, Fanfan, Jiang, Wenqi, Kimby, Eva, Huang, Huiqiang, Liu, Dongbing, Li, Zhi-Ming, Wu, Kui, Zhang, Huilai, and Pan-Hammarström, Qiang
- Abstract
Hepatitis B virus (HBV) infection has been associated with an increased risk for B-cell lymphomas. We previously showed that 20% of diffuse large B-cell lymphoma (DLBCL) patients from China, an endemic area of HBV infection, have chronic HBV infection (surface antigen–positive, HBsAg+) and are characterized by distinct clinical and genetic features. Here, we showed that 24% of follicular lymphoma (FL) Chinese patients are HBsAg+. Compared with the HBsAg− FL patients, HBsAg+ patients are younger, have a higher histological grade at diagnosis, and have a higher incidence of disease progression within 24 months. Moreover, by sequencing the genomes of 109 FL tumors, we observed enhanced mutagenesis and distinct genetic profile in HBsAg+ FLs, with a unique set of preferentially mutated genes (TNFAIP3, FAS, HIST1H1C, KLF2, TP53, PIM1, TMSB4X, DUSP2, TAGAP, LYN, and SETD2) but lack of the hallmark of HBsAg− FLs (ie, IGH/BCL2 translocations and CREBBP mutations). Transcriptomic analyses further showed that HBsAg+ FLs displayed gene-expression signatures resembling the activated B-cell–like subtype of diffuse large B-cell lymphoma, involving IRF4-targeted genes and NF-κB/MYD88 signaling pathways. Finally, we identified an increased infiltration of CD8+ memory T cells, CD4+ Th1 cells, and M1 macrophages and higher T-cell exhaustion gene signature in HBsAg+ FL samples. Taken together, we present new genetic/epigenetic evidence that links chronic HBV infection to B-cell lymphomagenesis, and HBV-associated FL is likely to have a distinct cell-of-origin and represent as a separate subtype of FL. Targetable genetic/epigenetic alterations identified in tumors and their associated tumor microenvironment may provide potential novel therapeutic approaches for this subgroup of patients.
- Published
- 2022
- Full Text
- View/download PDF
6. Distinct clinical and genetic features of hepatitis B virus–associated follicular lymphoma in Chinese patients
- Author
-
Ren, Weicheng, Wang, Xianhuo, Yang, Mingyu, Wan, Hui, Li, Xiaobo, Ye, Xiaofei, Meng, Bing, Li, Wei, Yu, Jingwei, Lei, Mengyue, Xie, Fanfan, Jiang, Wenqi, Kimby, Eva, Huang, Huiqiang, Liu, Dongbing, Li, Zhi-Ming, Wu, Kui, Zhang, Huilai, and Pan-Hammarström, Qiang
- Abstract
Hepatitis B virus (HBV) infection has been associated with an increased risk for B-cell lymphomas. We previously showed that 20% of diffuse large B-cell lymphoma (DLBCL) patients from China, an endemic area of HBV infection, have chronic HBV infection (surface antigen–positive, HBsAg+) and are characterized by distinct clinical and genetic features. Here, we showed that 24% of follicular lymphoma (FL) Chinese patients are HBsAg+. Compared with the HBsAg−FL patients, HBsAg+patients are younger, have a higher histological grade at diagnosis, and have a higher incidence of disease progression within 24 months. Moreover, by sequencing the genomes of 109 FL tumors, we observed enhanced mutagenesis and distinct genetic profile in HBsAg+FLs, with a unique set of preferentially mutated genes (TNFAIP3, FAS, HIST1H1C, KLF2, TP53, PIM1, TMSB4X, DUSP2, TAGAP, LYN, and SETD2) but lack of the hallmark of HBsAg−FLs (ie, IGH/BCL2translocations and CREBBPmutations). Transcriptomic analyses further showed that HBsAg+FLs displayed gene-expression signatures resembling the activated B-cell–like subtype of diffuse large B-cell lymphoma, involving IRF4-targeted genes and NF-κB/MYD88 signaling pathways. Finally, we identified an increased infiltration of CD8+memory T cells, CD4+Th1 cells, and M1 macrophages and higher T-cell exhaustion gene signature in HBsAg+FL samples. Taken together, we present new genetic/epigenetic evidence that links chronic HBV infection to B-cell lymphomagenesis, and HBV-associated FL is likely to have a distinct cell-of-origin and represent as a separate subtype of FL. Targetable genetic/epigenetic alterations identified in tumors and their associated tumor microenvironment may provide potential novel therapeutic approaches for this subgroup of patients.
- Published
- 2022
- Full Text
- View/download PDF
7. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
- Author
-
Casulo, Carla, Dixon, Jesse G., Le-Rademacher, Jennifer, Hoster, Eva, Hochster, Howard S., Hiddemann, Wolfgang, Marcus, Robert, Kimby, Eva, Herold, Michael, Sebban, Catherine, Gyan, Emmanuel, Foon, Kenneth, Nielsen, Tina, Vitolo, Umberto, Salles, Gilles A., Shi, Qian, and Flowers, Christopher R.
- Abstract
Observational studies and stand-alone trials indicate that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy (POD24), have poor outcomes. We performed a pooled analysis of 13 randomized clinical trials of patients with FL in the pre- and postrituximab eras to identify clinical factors that predict POD24. Logistic regression models evaluated the association between clinical factors and POD24. Cox regression evaluated the association between POD24 as a time-dependent factor and subsequent overall survival (OS). A landmark analysis evaluated the association of POD24 with OS for the subset of patients who were alive at 24 months after trial registration. Patients without progression at 24 months at baseline had favorable performance status (PS), limited-stage (I/II) disease, low-risk FL International Prognostic Index (FLIPI) score, normal baseline hemoglobin, and normal baseline β2 microglobulin (B2M) level. In a multivariable logistic regression model, male sex (odds ratio [OR], 1.30), PS ≥2 (OR, 1.63), B2M (≥3 mg/L; OR, 1.43), and high-risk FLIPI score (3-5; OR, 3.14) were associated with increased risk of progression before 24 months. In the time-dependent Cox model and the 24-month landmark analysis, POD24 was associated with poor subsequent OS (hazard ratio, 4.85 and 3.06, respectively). This is the largest pooled analysis of clinical trials data validating POD24 as a robust indicator of poor FL survival and identified clinical predictors of early death and progression that can aid in building comprehensive prognostic models incorporating clinical and molecular predictors of POD24.
- Published
- 2022
- Full Text
- View/download PDF
8. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
- Author
-
Casulo, Carla, Dixon, Jesse G., Le-Rademacher, Jennifer, Hoster, Eva, Hochster, Howard S., Hiddemann, Wolfgang, Marcus, Robert, Kimby, Eva, Herold, Michael, Sebban, Catherine, Gyan, Emmanuel, Foon, Kenneth, Nielsen, Tina, Vitolo, Umberto, Salles, Gilles A., Shi, Qian, and Flowers, Christopher R.
- Abstract
Observational studies and stand-alone trials indicate that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy (POD24), have poor outcomes. We performed a pooled analysis of 13 randomized clinical trials of patients with FL in the pre- and postrituximab eras to identify clinical factors that predict POD24. Logistic regression models evaluated the association between clinical factors and POD24. Cox regression evaluated the association between POD24 as a time-dependent factor and subsequent overall survival (OS). A landmark analysis evaluated the association of POD24 with OS for the subset of patients who were alive at 24 months after trial registration. Patients without progression at 24 months at baseline had favorable performance status (PS), limited-stage (I/II) disease, low-risk FL International Prognostic Index (FLIPI) score, normal baseline hemoglobin, and normal baseline β2microglobulin (B2M) level. In a multivariable logistic regression model, male sex (odds ratio [OR], 1.30), PS ≥2 (OR, 1.63), B2M (≥3 mg/L; OR, 1.43), and high-risk FLIPI score (3-5; OR, 3.14) were associated with increased risk of progression before 24 months. In the time-dependent Cox model and the 24-month landmark analysis, POD24 was associated with poor subsequent OS (hazard ratio, 4.85 and 3.06, respectively). This is the largest pooled analysis of clinical trials data validating POD24 as a robust indicator of poor FL survival and identified clinical predictors of early death and progression that can aid in building comprehensive prognostic models incorporating clinical and molecular predictors of POD24.
- Published
- 2022
- Full Text
- View/download PDF
9. Prognostic Significance of Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
- Author
-
Rosenwald, Andreas, Bens, Susanne, Advani, Ranjana, Barrans, Sharon, Copie-Bergman, Christiane, Elsensohn, Mad-Helenie, Natkunam, Yaso, Calaminici, Maria, Sander, Birgitta, Baia, Maryse, Smith, Alexandra, Painter, Daniel, Pham, Luu, Zhao, Shuchun, Ziepert, Marita, Jordanova, Ekaterina S., Molina, Thierry J., Kersten, Marie José, Kimby, Eva, and Klapper, Wolfram
- Published
- 2019
- Full Text
- View/download PDF
10. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
- Author
-
Casulo, Carla, Dixon, Jesse G., Ou, Fang-Shu, Hoster, Eva, Peterson, Bruce A., Hochster, Howard S., Brice, Pauline, Ladetto, Marco, Hiddemann, Wolfgang, Marcus, Robert, Kimby, Eva, Herold, Michael, Nielsen, Tina, Morschhauser, Franck, Rummel, Mathias, Hagenbeek, Anton, Vitolo, Umberto, Salles, Gilles A., Shi, Qian, and Flowers, Christopher R.
- Abstract
Limited data exist to describe the clinical features and outcomes for elderly patients with follicular lymphoma (FL). The Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) group performed a prospectively planned pooled analysis of individual patient data from first-line randomized controlled trials (RCTs) and examined associations between age (≤70 vs >70 years), clinical characteristics, and FL outcomes. We identified 18 multicenter clinical RCTs in the FLASH database that enrolled elderly patients (>70 years). Primary end points were early disease outcomes, CR24 and CR30, and progression-free survival (PFS) at 24 months (PFS24). Secondary end points were PFS and overall survival (OS). We identified 5922 previously untreated FL patients from 18 RCTs. Patients age >70 years (vs ≤70 years) more commonly had elevated lactate dehydrogenase, hemoglobin <12 g/dL, ECOG PS ≥2, and elevated β2-microglobulin. Median follow-up was 5.6 years. Patients >70 years did not differ from patients ≤70 years in rates of CR24, CR30, or PFS24. With a median OS of 14.6 years for all patients, median OS was 7.4 and 15.7 years for patients >70 and ≤70 years of age, respectively (hazard ratio = 2.35; 95% confidence interval = 2.03-2.73; P < .001). Age >70 years was a significant predictor of OS and PFS due to higher rates of death without progression, but not PFS24, CR24, or CR30. FL patients >70 years treated on trials have similar early disease outcomes to younger patients. There is no disease-specific outcome difference between age groups. Age alone should not disqualify patients from standard treatments or RCTs.
- Published
- 2021
- Full Text
- View/download PDF
11. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
- Author
-
Casulo, Carla, Dixon, Jesse G., Ou, Fang-Shu, Hoster, Eva, Peterson, Bruce A., Hochster, Howard S., Brice, Pauline, Ladetto, Marco, Hiddemann, Wolfgang, Marcus, Robert, Kimby, Eva, Herold, Michael, Nielsen, Tina, Morschhauser, Franck, Rummel, Mathias, Hagenbeek, Anton, Vitolo, Umberto, Salles, Gilles A., Shi, Qian, and Flowers, Christopher R.
- Abstract
Limited data exist to describe the clinical features and outcomes for elderly patients with follicular lymphoma (FL). The Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) group performed a prospectively planned pooled analysis of individual patient data from first-line randomized controlled trials (RCTs) and examined associations between age (≤70 vs >70 years), clinical characteristics, and FL outcomes. We identified 18 multicenter clinical RCTs in the FLASH database that enrolled elderly patients (>70 years). Primary end points were early disease outcomes, CR24 and CR30, and progression-free survival (PFS) at 24 months (PFS24). Secondary end points were PFS and overall survival (OS). We identified 5922 previously untreated FL patients from 18 RCTs. Patients age >70 years (vs ≤70 years) more commonly had elevated lactate dehydrogenase, hemoglobin <12 g/dL, ECOG PS ≥2, and elevated β2-microglobulin. Median follow-up was 5.6 years. Patients >70 years did not differ from patients ≤70 years in rates of CR24, CR30, or PFS24. With a median OS of 14.6 years for all patients, median OS was 7.4 and 15.7 years for patients >70 and ≤70 years of age, respectively (hazard ratio = 2.35; 95% confidence interval = 2.03-2.73; P< .001). Age >70 years was a significant predictor of OS and PFS due to higher rates of death without progression, but not PFS24, CR24, or CR30. FL patients >70 years treated on trials have similar early disease outcomes to younger patients. There is no disease-specific outcome difference between age groups. Age alone should not disqualify patients from standard treatments or RCTs.
- Published
- 2021
- Full Text
- View/download PDF
12. Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.
- Author
-
Lockmer, Sandra, Østenstad, Bjørn, Hagberg, Hans, Holte, Harald, Johansson, Ann-Sofie, Wahlin, Björn Engelbrekt, Wader, Karin Fahl, Steen, Chloé Beate, Meyer, Peter, Maisenhølder, Martin, Smedby, Karin Ekström, Brown, Peter, and Kimby, Eva
- Published
- 2018
- Full Text
- View/download PDF
13. The Proliferative History Index, Epicmit, Derived from Genome-Wide Epigenomic Profiling, Is a Key Driver of Clinical Survival in Splenic Marginal Zone Lymphoma
- Author
-
Parker, Helen, Mirandari, Amatta, Jaramillo-Oquendo, Carolina, Duran-Ferrer, Marti, Stevens, Ben, Buermann, Lara, Amarasinghe, Harindra Eranthi, Thomas, Jaya, Carr, Louise J., Syeda, Shama, Sakthipakan, Methusha, Parry, Marina, Davies, Zadie, McIver-Brown, Neil, Xochelli, Aliki, Ennis, Sarah, Scarfo, Lydia, Ghia, Paolo, Kalpadakis, Christina H., Pangalis, Gerassimos, Rossi, Davide, Wagner, Simon, Ahearne, Matthew, Seifert, Marc, Plass, Christoph, Weichenhan, Dieter, Kimby, Eva, Sutton, Lesley Ann, Rosenquist, Richard, Forconi, Francesco, Stamatopoulos, Kostas, Salido, Marta, Ferrer, Ana, Thieblemont, Catherine, Oscier, David Graham, Walewska, Renata, Rose-Zerilli, Matthew JJ, Gibson, Jane, Martin Subero, Iñaki I., Oakes, Christopher C., Bryant, Dean J., and Strefford, Jonathan C.
- Abstract
The epiCMIT (epigenetically-determined Cumulative MIToses) mitotic clock (Durran-Ferrer, 2020) tracks DNA hypo- and hyper-methylation changes in heterochromatin and H3K27me3-containing chromatin, respectively, providing a comprehensive record of B cell mitotic history (pre- and post-malignant transformation). Higher epiCMIT levels correlate with poor survival in CLL and MCL, suggesting that a greater mitotic history predicts future proliferative capacity. However, no studies have investigated epiCMIT in splenic marginal zone lymphoma (SMZL).
- Published
- 2023
- Full Text
- View/download PDF
14. Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial
- Author
-
Zucca, Emanuele, Schaer, Saemi, Vanazzi, Anna, Østenstad, Bjørn, Mey, Ulrich, Rauch, Daniel, Wahlin, Björn E., Hitz, Felicitas, Hernberg, Micaela, Johansson, Ann-Sofie, Brown, Peter de Nully, Hagberg, Hans, Ferreri, Andrés José María, Krasniqi, Fatime, Voegeli, Michèle, Novak, Urban, Zander, Thilo, Bersvendsen, Hanne, Mamot, Christoph, Mingrone, Walter, Stathis, Anastasios, Dirnhofer, Stefan, Hayoz, Stefanie, and Kimby, Eva
- Abstract
Background:The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) conducted the SAKK 35/10 randomized phase-2 trial (NCT0137605) to compare the effectiveness of rituximab (R) alone versus R combined with lenalidomide (L) as the initial treatment for symptomatic follicular lymphoma (FL). The primary endpoint analysis, which demonstrated higher complete remission (CR) rates with the combination therapy, was previously reported (Zucca et al. Blood 2019). This report provides a long-term analysis of time-to-event endpoints with a median follow-up of approximately 10 years.
- Published
- 2023
- Full Text
- View/download PDF
15. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
- Author
-
Zucca, Emanuele, Rondeau, Stephanie, Vanazzi, Anna, Østenstad, Bjørn, Mey, Ulrich J. M., Rauch, Daniel, Wahlin, Björn E., Hitz, Felicitas, Hernberg, Micaela, Johansson, Ann-Sofie, de Nully Brown, Peter, Hagberg, Hans, Ferreri, Andrés J. M., Lohri, Andreas, Novak, Urban, Zander, Thilo, Bersvendsen, Hanne, Bargetzi, Mario, Mingrone, Walter, Krasniqi, Fatime, Dirnhofer, Stefan, Hayoz, Stefanie, Hawle, Hanne, Vilei, Simona Berardi, Ghielmini, Michele, and Kimby, Eva
- Abstract
The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab plus lenalidomide in untreated follicular lymphoma patients in need of systemic therapy. Patients were randomized to rituximab (375 mg/m2 IV on day 1 of weeks 1-4 and repeated during weeks 12-15 in responding patients) or rituximab (same schedule) in combination with lenalidomide (15 mg orally daily for 18 weeks). Primary end point was complete response (CR)/unconfirmed CR (CRu) rate at 6 months. In total, 77 patients were allocated to rituximab monotherapy and 77 to the combination (47% poor-risk Follicular Lymphoma International Prognostic Index score in each arm). A significantly higher CR/CRu rate at 6 months was documented in the combination arm by the investigators (36%; 95% confidence interval [CI], 26%-48% vs 25%; 95% CI, 16%-36%) and confirmed by an independent response review of computed tomography scans only (61%; 95% CI, 49%-72% vs 36%; 95% CI, 26%-48%). After a median follow-up of 4 years, significantly higher 30-month CR/CRu rates and longer progression-free survival (PFS) and time to next treatment (TTNT) were observed for the combination. Overall survival (OS) rates were similar in both arms (=90%). Toxicity grade =3 was more common in the combination arm (56% vs 22% of patients), mainly represented by neutropenia (23% vs 7%). Addition of lenalidomide to rituximab significantly improved CR/CRu rates, PFS, and TTNT, with expected higher, but manageable toxicity. The excellent OS in both arms suggests that chemotherapy-free strategies should be further explored. This trial was registered at www.clinicaltrials.gov as #NCT01307605.
- Published
- 2019
- Full Text
- View/download PDF
16. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
- Author
-
Zucca, Emanuele, Rondeau, Stephanie, Vanazzi, Anna, Østenstad, Bjørn, Mey, Ulrich J.M., Rauch, Daniel, Wahlin, Björn E., Hitz, Felicitas, Hernberg, Micaela, Johansson, Ann-Sofie, de Nully Brown, Peter, Hagberg, Hans, Ferreri, Andrés J.M., Lohri, Andreas, Novak, Urban, Zander, Thilo, Bersvendsen, Hanne, Bargetzi, Mario, Mingrone, Walter, Krasniqi, Fatime, Dirnhofer, Stefan, Hayoz, Stefanie, Hawle, Hanne, Vilei, Simona Berardi, Ghielmini, Michele, and Kimby, Eva
- Abstract
The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab plus lenalidomide in untreated follicular lymphoma patients in need of systemic therapy. Patients were randomized to rituximab (375 mg/m2IV on day 1 of weeks 1-4 and repeated during weeks 12-15 in responding patients) or rituximab (same schedule) in combination with lenalidomide (15 mg orally daily for 18 weeks). Primary end point was complete response (CR)/unconfirmed CR (CRu) rate at 6 months. In total, 77 patients were allocated to rituximab monotherapy and 77 to the combination (47% poor-risk Follicular Lymphoma International Prognostic Index score in each arm). A significantly higher CR/CRu rate at 6 months was documented in the combination arm by the investigators (36%; 95% confidence interval [CI], 26%-48% vs 25%; 95% CI, 16%-36%) and confirmed by an independent response review of computed tomography scans only (61%; 95% CI, 49%-72% vs 36%; 95% CI, 26%-48%). After a median follow-up of 4 years, significantly higher 30-month CR/CRu rates and longer progression-free survival (PFS) and time to next treatment (TTNT) were observed for the combination. Overall survival (OS) rates were similar in both arms (≥90%). Toxicity grade ≥3 was more common in the combination arm (56% vs 22% of patients), mainly represented by neutropenia (23% vs 7%). Addition of lenalidomide to rituximab significantly improved CR/CRu rates, PFS, and TTNT, with expected higher, but manageable toxicity. The excellent OS in both arms suggests that chemotherapy-free strategies should be further explored. This trial was registered at www.clinicaltrials.govas #NCT01307605.
- Published
- 2019
- Full Text
- View/download PDF
17. Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study
- Author
-
Wästerlid, Tove, Warnqvist, Anna, Weibull, Caroline E., Wahlin, Björn E, Andersson, P-O, Enblad, Gunilla, Kimby, Eva, and Ekstroem Smedby, Karin
- Published
- 2022
- Full Text
- View/download PDF
18. Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study
- Author
-
Wästerlid, Tove, Warnqvist, Anna, Weibull, Caroline E., Wahlin, Björn E, Andersson, P-O, Enblad, Gunilla, Kimby, Eva, and Ekstroem Smedby, Karin
- Published
- 2022
- Full Text
- View/download PDF
19. Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma
- Author
-
Bai, Baoyan, Wise, Jillian F., Vodák, Daniel, Nakken, Sigve, Sharma, Ankush, Blaker, Yngvild Nuvin, Brodtkorb, Marianne, Hilden, Vera, Trøen, Gunhild, Ren, Weicheng, Lorenz, Suzanne, Lawrence, Michael S., Myklebost, Ola, Kimby, Eva, Pan-Hammarstrom, Qiang, Meza-Zepeda, Leonardo, Beiske, Klaus, Smeland, Erlend B., Hovig, Eivind, Lingjærde, Ole Christian, Holte, Harald, and Myklebust, June Helen
- Published
- 2022
- Full Text
- View/download PDF
20. Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma
- Author
-
Bai, Baoyan, Wise, Jillian F., Vodák, Daniel, Nakken, Sigve, Sharma, Ankush, Blaker, Yngvild Nuvin, Brodtkorb, Marianne, Hilden, Vera, Trøen, Gunhild, Ren, Weicheng, Lorenz, Suzanne, Lawrence, Michael S., Myklebost, Ola, Kimby, Eva, Pan-Hammarstrom, Qiang, Meza-Zepeda, Leonardo, Beiske, Klaus, Smeland, Erlend B., Hovig, Eivind, Lingjærde, Ole Christian, Holte, Harald, and Myklebust, June Helen
- Published
- 2022
- Full Text
- View/download PDF
21. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.
- Author
-
Qian Shi, Flowers, Christopher R., Hiddemann, Wolfgang, Marcus, Robert, Herold, Michael, Hagenbeek, Anton, Kimby, Eva, Hochster, Howard, Vitolo, Umberto, Peterson, Bruce A., Gyan, Emmanuel, Ghielmini, Michele, Nielsen, Tina, De Bedout, Sabine, Fu, Tommy, Valente, Nancy, Fowler, Nathan H., Hoster, Eva, Ladetto, Marco, and Morschhauser, Franck
- Published
- 2017
- Full Text
- View/download PDF
22. Reply to M. Sorigue et al.
- Author
-
Lockmer, Sandra, Østenstad, Bjørn, Hagberg, Hans, Holte, Harald, Wahlin, Björn Engelbrekt, Wader, Karin Fahl, Smedby, Karin Ekström, Brown, Peter, and Kimby, Eva
- Published
- 2019
- Full Text
- View/download PDF
23. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
- Author
-
Dreger, Peter, Ghia, Paolo, Schetelig, Johannes, van Gelder, Michel, Kimby, Eva, Michallet, Mauricette, Moreno, Carol, Robak, Tadeusz, Stilgenbauer, Stephan, and Montserrat, Emili
- Abstract
High-risk chronic lymphocytic leukemia (CLL) has been defined by clinical and/or genetic resistance (TP53 abnormalities) to treatment with chemoimmunotherapy (CIT). With the availability of pathway inhibitors (PIs), such as kinase inhibitors and BCL2 antagonists, the outlook of CIT-resistant patients has dramatically improved. Here, we propose a revision of the concept of high-risk CLL, driven by TP53 abnormalities and response to treatment with PI. CLL high-risk-I, CIT-resistant is defined by clinically CIT-resistant disease with TP53 aberrations, but fully responsive to PI. This category is largely the domain of PI-based therapy, and cellular therapy (ie, allogeneic hematopoietic cell transplantation) remains an option only in selected patients with low individual procedure-related risk. In CLL high-risk-II, CIT- and PI-resistant, characterized by increasing exhaustion of pharmacological treatment possibilities, cellular therapies (including chimeric antigen receptor-engineered T cells) should be considered in patients eligible for these procedures. Moreover, molecular and cellular therapies are not mutually exclusive and could be used synergistically to exploit their full potential.
- Published
- 2018
- Full Text
- View/download PDF
24. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
- Author
-
Dreger, Peter, Ghia, Paolo, Schetelig, Johannes, van Gelder, Michel, Kimby, Eva, Michallet, Mauricette, Moreno, Carol, Robak, Tadeusz, Stilgenbauer, Stephan, Montserrat, Emili, (ERIC), on behalf of the European Research Initiative on CLL, Blood, the European Society for, and M
- Abstract
High-risk chronic lymphocytic leukemia (CLL) has been defined by clinical and/or genetic resistance (TP53abnormalities) to treatment with chemoimmunotherapy (CIT). With the availability of pathway inhibitors (PIs), such as kinase inhibitors and BCL2 antagonists, the outlook of CIT-resistant patients has dramatically improved. Here, we propose a revision of the concept of high-risk CLL, driven by TP53abnormalities and response to treatment with PI. CLL high-risk-I, CIT-resistant is defined by clinically CIT-resistant disease with TP53aberrations, but fully responsive to PI. This category is largely the domain of PI-based therapy, and cellular therapy (ie, allogeneic hematopoietic cell transplantation) remains an option only in selected patients with low individual procedure-related risk. In CLL high-risk-II, CIT- and PI-resistant, characterized by increasing exhaustion of pharmacological treatment possibilities, cellular therapies (including chimeric antigen receptor-engineered T cells) should be considered in patients eligible for these procedures. Moreover, molecular and cellular therapies are not mutually exclusive and could be used synergistically to exploit their full potential.
- Published
- 2018
- Full Text
- View/download PDF
25. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
- Author
-
Federico, Massimo, Caballero Barrigón, María Dolores, Marcheselli, Luigi, Tarantino, Vittoria, Manni, Martina, Sarkozy, Clementine, Alonso-Álvarez, Sara, Wondergem, Marielle, Cartron, Guillaume, Lopez-Guillermo, Armando, Issa, Djamila, Morschhauser, Franck, Alcoceba, Miguel, Kimby, Eva, Rusconi, Chiara, Chamuleau, Martine, Holte, Harald, Lockmer, Sandra, Montoto, Silvia, Gomes da Silva, Maria, Aurer, Igor, Zucca, Emanuele, Paszkiewicz-Kozik, Ewa, Minoia, Carla, Skrypets, Tetiana, Blaker, Yngvild Nuvin, Salles, Gilles, and Coiffier, Bertrand
- Abstract
Histological transformation of follicular lymphoma to aggressive lymphoma is a serious event with a substantial effect on patient outcome. The aim of the Aristotle study was to assess the effect of rituximab on the risk of histological transformation and its outcome.
- Published
- 2018
- Full Text
- View/download PDF
26. Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia
- Author
-
Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M., Buske, Christian, Castillo, Jorge J., García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C., Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J., Treon, Steven P., and Dimopoulos, Meletios A.
- Abstract
Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of the International Workshop on Waldenström’s Macroglobulinemia (IWWM). At IWWM-8, a task force for treatment recommendations was impanelled to review recently published and ongoing clinical trial data as well as the impact of new mutations (MYD88 and CXCR4) on treatment decisions, indications for B-cell receptor and proteasome inhibitors, and future clinical trial initiatives for WM patients. The panel concluded that therapeutic strategies in WM should be based on individual patient and disease characteristics. Chemoimmunotherapy combinations with rituximab and cyclophosphamide-dexamethasone, bendamustine, or bortezomib-dexamethasone provide durable responses and are still indicated in most patients. Approval of the BTK inhibitor ibrutinib in the United States and Europe represents a novel and effective treatment option for both treatment-naive and relapsing patients. Other B-cell receptor inhibitors, second-generation proteasome inhibitors (eg, carfilzomib), and mammalian target of rapamycin inhibitors are promising and may increase future treatment options. Active enrollment in clinical trials whenever possible was endorsed by the panel for most patients with WM.
- Published
- 2016
- Full Text
- View/download PDF
27. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia
- Author
-
Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M., Buske, Christian, Castillo, Jorge J., García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C., Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J., Treon, Steven P., and Dimopoulos, Meletios A.
- Abstract
Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of the International Workshop on Waldenström's Macroglobulinemia (IWWM). At IWWM-8, a task force for treatment recommendations was impanelled to review recently published and ongoing clinical trial data as well as the impact of new mutations (MYD88 and CXCR4) on treatment decisions, indications for B-cell receptor and proteasome inhibitors, and future clinical trial initiatives for WM patients. The panel concluded that therapeutic strategies in WM should be based on individual patient and disease characteristics. Chemoimmunotherapy combinations with rituximab and cyclophosphamide-dexamethasone, bendamustine, or bortezomib-dexamethasone provide durable responses and are still indicated in most patients. Approval of the BTK inhibitor ibrutinib in the United States and Europe represents a novel and effective treatment option for both treatment-naive and relapsing patients. Other B-cell receptor inhibitors, second-generation proteasome inhibitors (eg, carfilzomib), and mammalian target of rapamycin inhibitors are promising and may increase future treatment options. Active enrollment in clinical trials whenever possible was endorsed by the panel for most patients with WM.
- Published
- 2016
- Full Text
- View/download PDF
28. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
- Author
-
Dreger, Peter, Schetelig, Johannes, Andersen, Niels, Corradini, Paolo, van Gelder, Michel, Gribben, John, Kimby, Eva, Michallet, Mauricette, Moreno, Carol, Stilgenbauer, Stephan, and Montserrat, Emili
- Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [<24 months] to chemoimmunotherapy, and/or presence of del[17p]/TP53mutations). Currently, treatment algorithms for HR-CLL are being challenged by the introduction of novel classes of drugs. Among them, BCR signal inhibitors (BCRi) and B-cell lymphoma 2 antagonists (BCL2a) appear particularly promising. As a result of the growing body of favorable outcome data reported for BCRi/BCL2a, uncertainty is emerging on how to advise patients with HR-CLL about indication for and timing of HSCT. This article provides an overview of currently available evidence and theoretical considerations to guide this difficult decision process. Until the risks and benefits of different treatment strategies are settled, all patients with HR-CLL should be considered for treatment with BCRi/BCL2a. For patients who respond to these agents, there are 2 treatment possibilities: (1) performing an HSCT or (2) continuing treatment with the novel drug. Individual disease-specific and transplant-related risk factors, along with patient’s preferences, should be taken into account when recommending one of these treatments over the other.
- Published
- 2014
- Full Text
- View/download PDF
29. Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
- Author
-
Pettengell, Ruth, Schmitz, Norbert, Gisselbrecht, Christian, Smith, Graeme, Patton, William N., Metzner, Bernd, Caballero, Dolores, Tilly, Herve, Walewski, Jan A., Bence-Bruckler, Isabelle, To, Bik, Geisler, Christian H., Schots, Rik, Kimby, Eva, Taverna, Christian J., Kozák, Tomáš, Dreger, Peter, Uddin, Ruzena, de Elvira, Carmen Ruiz, and Goldstone, Anthony H.
- Published
- 2013
- Full Text
- View/download PDF
30. Tolerability and safety of rituximab (MabThera®).
- Author
-
Kimby, Eva
- Abstract
Summary: Rituximab, a human/mouse chimeric anti-CD20 antibody, has become part of standard therapy for patients with CD20-expressing B-cell lymphoma, and is currently under investigation for other indications including autoimmune diseases, in particular rheumatoid arthritis (RA). Its characteristic tolerability profile was established soon after clinical testing began and compares favourably with chemotherapy. The majority of patients experience mild to moderate infusion-related reactions (IRRs) during the first administration of rituximab, but the incidence decreases markedly with subsequent infusions. Current data suggest that the type of adverse events in patients with RA are similar to those in lymphoma, but that adverse events related to the rituximab infusions are less severe and less frequent. Rituximab induces a rapid depletion of normal CD20-expressing B-cells in the peripheral blood, and levels remain low or undetectable for 2–6 months before returning to pretreatment levels, generally within 12 months. Serum immunoglobulin levels remain largely stable, although a reduction in IgM has been described. T-cells are unaffected by rituximab and consequently opportunistic infections rarely occur in association with rituximab therapy. When used in combination with a variety of chemotherapeutic regimens, rituximab does not add to the toxicity of chemotherapy, with the exception of a higher rate of neutropenia. However, this does not translate into a higher infection rate. Over 540000 patients worldwide have now received rituximab and serious adverse reactions have occurred in a small minority of patients, but for the great majority of patients, rituximab is safe and well tolerated. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
31. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
- Author
-
Dimopoulos, Meletios A., Kastritis, Efstathios, Owen, Roger G., Kyle, Robert A., Landgren, Ola, Morra, Enrica, Leleu, Xavier, García-Sanz, Ramón, Munshi, Nikhil, Anderson, Kenneth C., Terpos, Evangelos, Ghobrial, Irene M., Morel, Pierre, Maloney, David, Rummel, Mathias, Leblond, Véronique, Advani, Ranjana H., Gertz, Morie A., Kyriakou, Charalampia, Thomas, Sheeba K., Barlogie, Bart, Gregory, Stephanie A., Kimby, Eva, Merlini, Giampaolo, and Treon, Steven P.
- Abstract
Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As part of the IWWM-7 and based on recently published and ongoing clinical trials, the panels updated treatment recommendations. Therapeutic strategy in WM should be based on individual patient and disease characteristics (age, comorbidities, need for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related complications, hyperviscosity, and neuropathy). Mature data show that rituximab combinations with cyclophosphamide/dexamethasone, bendamustine, or bortezomib/dexamethasone provided durable responses and are indicated for most patients. New monoclonal antibodies (ofatumumab), second-generation proteasome inhibitors (carfilzomib), mammalian target of rapamycin inhibitors, and Bruton's tyrosine kinase inhibitors are promising and may expand future treatment options. A different regimen is typically recommended for relapsed or refractory disease. In selected patients with relapsed disease after long-lasting remission, reuse of a prior effective regimen may be appropriate. Autologous stem cell transplantation may be considered in young patients with chemosensitive disease and in newly diagnosed patients with very-high-risk features. Active enrollment of patients with WM in clinical trials is encouraged.
- Published
- 2014
- Full Text
- View/download PDF
32. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
- Author
-
Dimopoulos, Meletios A., Kastritis, Efstathios, Owen, Roger G., Kyle, Robert A., Landgren, Ola, Morra, Enrica, Leleu, Xavier, García-Sanz, Ramón, Munshi, Nikhil, Anderson, Kenneth C., Terpos, Evangelos, Ghobrial, Irene M., Morel, Pierre, Maloney, David, Rummel, Mathias, Leblond, Véronique, Advani, Ranjana H., Gertz, Morie A., Kyriakou, Charalampia, Thomas, Sheeba K., Barlogie, Bart, Gregory, Stephanie A., Kimby, Eva, Merlini, Giampaolo, and Treon, Steven P.
- Abstract
Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As part of the IWWM-7 and based on recently published and ongoing clinical trials, the panels updated treatment recommendations. Therapeutic strategy in WM should be based on individual patient and disease characteristics (age, comorbidities, need for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related complications, hyperviscosity, and neuropathy). Mature data show that rituximab combinations with cyclophosphamide/dexamethasone, bendamustine, or bortezomib/dexamethasone provided durable responses and are indicated for most patients. New monoclonal antibodies (ofatumumab), second-generation proteasome inhibitors (carfilzomib), mammalian target of rapamycin inhibitors, and Bruton's tyrosine kinase inhibitors are promising and may expand future treatment options. A different regimen is typically recommended for relapsed or refractory disease. In selected patients with relapsed disease after long-lasting remission, reuse of a prior effective regimen may be appropriate. Autologous stem cell transplantation may be considered in young patients with chemosensitive disease and in newly diagnosed patients with very-high-risk features. Active enrollment of patients with WM in clinical trials is encouraged.
- Published
- 2014
- Full Text
- View/download PDF
33. microRNA-34b/con chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia
- Author
-
Deneberg, Stefan, Kanduri, Meena, Ali, Dina, Bengtzen, Sofia, Karimi, Mohsen, Qu, Ying, Kimby, Eva, Mansouri, Larry, Rosenquist, Richard, Lennartsson, Andreas, and Lehmann, Sören
- Abstract
A commonly deleted region in chronic lymphocytic leukemia (CLL) is the 11q22–23 region, which encompasses the ATMgene. Evidence suggests that tumor suppressor genes other than ATMare likely to be involved in CLL with del(11q). A microRNA (miR) cluster including the miR-34band miR-34cgenes is located, among other genes, within the commonly deleted region (CDR) at 11q. Interestingly, these miRs are part of the TP53network and have been shown to be epigenetically regulated. In this study, we investigated the expression and methylation status of these miRs in a well-characterized cohort of CLL, including cases with/without 11q-deletion. We show that the miR-34b/cpromoter was aberrantly hypermethylated in a large proportion of CLL cases (48%, 25/52 cases). miR-34b/c expression correlated inversely to DNA methylation (P= 0.003), and presence of high H3K37me3 further suppressed expression regardless of methylation status. Furthermore, increased miR-34b/cmethylation inversely correlated with the presence of 11q-deletion, indicating that methylation and del(11q) independently silence these miRs. Finally, 5-azacytidine and trichostatin A exposure synergistically increased the expression of miR-34b/c in CLL cells, and transfection of miR-34b or miR-34c into HG3 CLL cells significantly increased apoptosis. Altogether, our novel data suggest that miR-34b/c is a candidate tumor suppressor that is epigenetically silenced in CLL.
- Published
- 2014
- Full Text
- View/download PDF
34. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL
- Author
-
Geisler, Christian H., van t’ Veer, Mars B., Jurlander, Jesper, Walewski, Jan, Tjønnfjord, Geir, Itälä Remes, Maija, Kimby, Eva, Kozak, Tomas, Polliack, Aaron, Wu, Ka Lung, Wittebol, Shulamiet, Abrahamse-Testroote, Martine C. J., Doorduijn, Jeanette, Ghidey Alemayehu, Wendimagegn, and van Oers, Marinus H. J.
- Abstract
The randomized Haemato Oncology Foundation for Adults in The Netherlands 68 phase 3 trial compared front-line chemotherapy with chemotherapy plus the CD52 monoclonal antibody alemtuzumab for high-risk chronic lymphocytic leukemia, defined as at least 1 of the following: unmutated immunoglobulin heavy chain genes, deletion 17p or 11q, or trisomy 12. Fit patients were randomized to receive either 6 28-day cycles of oral FC chemotherapy (days 1 through 3: fludarabine 40 mg/m2 per day and cyclophosphamide 250 mg/m2 per day: n = 139) or FC plus subcutaneous alemtuzumab 30 mg day 1 (FCA, n = 133). FCA prolonged the primary end point, progression-free survival (3-year progression-free survival 53 vs 37%, P = .01), but not the secondary end point, overall survival (OS). However, a post hoc analysis showed that FCA increased OS in patients younger than 65 years (3-year OS 85% vs 76%, P = .035). FCA also increased the overall response rate (88 vs 78%, P = .036), and the bone marrow minimal residual disease–negative complete remission rate (64% vs 43%, P = .016). Opportunistic infections were more frequent following FCA, but without an increase in treatment related mortality (FCA: 3.8%, FC: 4.3%). FCA improves progression-free survival in high-risk chronic lymphocytic leukemia. As anticipated, FCA is more immunosuppressive than FC, but with due vigilance, does not lead to a higher treatment-related mortality. This study was registered at www.trialregister.nl as trial no. NTR529.
- Published
- 2014
- Full Text
- View/download PDF
35. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL
- Author
-
Geisler, Christian H., van t' Veer, Mars B., Jurlander, Jesper, Walewski, Jan, Tjønnfjord, Geir, Itälä Remes, Maija, Kimby, Eva, Kozak, Tomas, Polliack, Aaron, Wu, Ka Lung, Wittebol, Shulamiet, Abrahamse-Testroote, Martine C.J., Doorduijn, Jeanette, Ghidey Alemayehu, Wendimagegn, and van Oers, Marinus H.J.
- Abstract
The randomized Haemato Oncology Foundation for Adults in The Netherlands 68 phase 3 trial compared front-line chemotherapy with chemotherapy plus the CD52 monoclonal antibody alemtuzumab for high-risk chronic lymphocytic leukemia, defined as at least 1 of the following: unmutated immunoglobulin heavy chain genes, deletion 17p or 11q, or trisomy 12. Fit patients were randomized to receive either 6 28-day cycles of oral FC chemotherapy (days 1 through 3: fludarabine 40 mg/m2per day and cyclophosphamide 250 mg/m2per day: n = 139) or FC plus subcutaneous alemtuzumab 30 mg day 1 (FCA, n = 133). FCA prolonged the primary end point, progression-free survival (3-year progression-free survival 53 vs 37%, P= .01), but not the secondary end point, overall survival (OS). However, a post hoc analysis showed that FCA increased OS in patients younger than 65 years (3-year OS 85% vs 76%, P= .035). FCA also increased the overall response rate (88 vs 78%, P= .036), and the bone marrow minimal residual disease–negative complete remission rate (64% vs 43%, P= .016). Opportunistic infections were more frequent following FCA, but without an increase in treatment related mortality (FCA: 3.8%, FC: 4.3%). FCA improves progression-free survival in high-risk chronic lymphocytic leukemia. As anticipated, FCA is more immunosuppressive than FC, but with due vigilance, does not lead to a higher treatment-related mortality. This study was registered at www.trialregister.nlas trial no. NTR529.
- Published
- 2014
- Full Text
- View/download PDF
36. Nordic MCL3 study: 90Y-ibritumomab-tiuxetanadded to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
- Author
-
Kolstad, Arne, Laurell, Anna, Jerkeman, Mats, Grønbæk, Kirsten, Elonen, Erkki, Räty, Riikka, Pedersen, Lone Bredo, Loft, Annika, Bogsrud, Trond Velde, Kimby, Eva, Hansen, Per Boye, Fagerli, Unn-Merete, Nilsson-Ehle, Herman, Lauritzsen, Grete Fossum, Lehmann, Anne Kristine, Sundstrom, Christer, Karjalainen-Lindsberg, Marja-Liisa, Ralfkiaer, Elisabeth, Ehinger, Mats, Delabie, Jan, Bentzen, Hans, Schildt, Jukka, Kostova-Aherdan, Kamelia, Frederiksen, Henrik, Brown, Peter de Nully, and Geisler, Christian H.
- Abstract
The main objective of the MCL3 study was to improve outcome for patients not in complete remission (CR) before transplant by adding 90Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen. One hundred sixty untreated, stage II-IV mantle cell lymphoma patients <66 years received rituximab (R)–maxi–CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) alternating with R-high-dose cytarabine (6 cycles total), followed by high-dose BEAM/C (bis-chloroethylnitrosourea, etoposide, cytarabine, and melphalan or cyclophosphamide) and autologous stem cell transplantation from 2005 to 2009. Zevalin (0.4 mCi/kg) was given to responders not in CR before transplant. Overall response rate pretransplant was 97%. The outcome did not differ from that of the historic control: the MCL2 trial with similar treatment except for Zevalin. Overall survival (OS), event-free survival (EFS), and progression-free survival (PFS) at 4 years were 78%, 62%, and 71%, respectively. For responding non-CR patients who received Zevalin, duration of response was shorter than for the CR group. Inferior PFS, EFS, and OS were predicted by positron emission tomography (PET) positivity pretransplant and detectable minimal residual disease (MRD) after transplant. In conclusion, positive PET and MRD were strong predictors of outcome. Intensification with Zevalin may be too late to improve the outcome of patients not in CR before transplant. This trial was registered at www.clinicaltrials.govas #NCT00514475.
- Published
- 2014
- Full Text
- View/download PDF
37. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
- Author
-
Kolstad, Arne, Laurell, Anna, Jerkeman, Mats, Grønbæk, Kirsten, Elonen, Erkki, Räty, Riikka, Pedersen, Lone Bredo, Loft, Annika, Bogsrud, Trond Velde, Kimby, Eva, Hansen, Per Boye, Fagerli, Unn-Merete, Nilsson-Ehle, Herman, Lauritzsen, Grete Fossum, Lehmann, Anne Kristine, Sundstrom, Christer, Karjalainen-Lindsberg, Marja-Liisa, Ralfkiaer, Elisabeth, Ehinger, Mats, Delabie, Jan, Bentzen, Hans, Schildt, Jukka, Kostova-Aherdan, Kamelia, Frederiksen, Henrik, Brown, Peter de Nully, and Geisler, Christian H.
- Abstract
The main objective of the MCL3 study was to improve outcome for patients not in complete remission (CR) before transplant by adding 90Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen. One hundred sixty untreated, stage II-IV mantle cell lymphoma patients <66 years received rituximab (R)–maxi–CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) alternating with R-high-dose cytarabine (6 cycles total), followed by high-dose BEAM/C (bis-chloroethylnitrosourea, etoposide, cytarabine, and melphalan or cyclophosphamide) and autologous stem cell transplantation from 2005 to 2009. Zevalin (0.4 mCi/kg) was given to responders not in CR before transplant. Overall response rate pretransplant was 97%. The outcome did not differ from that of the historic control: the MCL2 trial with similar treatment except for Zevalin. Overall survival (OS), event-free survival (EFS), and progression-free survival (PFS) at 4 years were 78%, 62%, and 71%, respectively. For responding non-CR patients who received Zevalin, duration of response was shorter than for the CR group. Inferior PFS, EFS, and OS were predicted by positron emission tomography (PET) positivity pretransplant and detectable minimal residual disease (MRD) after transplant. In conclusion, positive PET and MRD were strong predictors of outcome. Intensification with Zevalin may be too late to improve the outcome of patients not in CR before transplant. This trial was registered at www.clinicaltrials.gov as #NCT00514475.
- Published
- 2014
- Full Text
- View/download PDF
38. Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma
- Author
-
Spasevska, Ivana, Josefsson, Sarah, Blaker, Yngvild Nuvin, Steen, Chloe B., Sharma, Ankush, Kushekhar, Kushi, Meyer, Saskia, Kolstad, Arne, Beiske, Klaus, Holte, Harald, Østenstad, Bjørn, Kimby, Eva, Olweus, Johanna, Tasken, Kjetil, Lorenz, Suzanne, Smeland, Erlend B., Alizadeh, Ash A., Huse, Kanutte, and Myklebust, June Helen
- Abstract
Introduction:Regulatory T cells (Tregs), a highly immunosuppressive subset of CD4 T cells, are enriched in B-cell non-Hodgkin lymphoma (NHL) and constitute a barrier to potent antitumor immune responses. Despite extensive studies, the significance of tumor-infiltrating Tregs on disease outcome is unclear and while Tregs may express co-inhibitory and co-stimulatory receptors, the role of intratumoral Tregs in the context of immune checkpoint therapy remains elusive. Emerging evidence suggests heterogeneity among Tregs and their suppressive capacities in cancer, emphasizing the need for additional markers to identify highly suppressive Tregs. Therefore, an in-depth characterization of Treg heterogeneity in NHL could provide important insight into the disease pathogenesis and have implications for rational drug design.
- Published
- 2020
- Full Text
- View/download PDF
39. Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden
- Author
-
Weibull, Caroline, Wahlin, Björn E, Lockmer, Sandra, Enblad, Gunilla, Andersson, Per-Ola, Kimby, Eva, and Smedby, Karin E.
- Abstract
Weibull: Janssen Cilag: Research Funding. Wahlin:Gilead Sciences: Research Funding; Roche: Consultancy, Research Funding. Smedby:Takeda: Research Funding; Janssen: Research Funding; Celgene: Consultancy.
- Published
- 2020
- Full Text
- View/download PDF
40. Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma
- Author
-
Spasevska, Ivana, Josefsson, Sarah, Blaker, Yngvild Nuvin, Steen, Chloe B., Sharma, Ankush, Kushekhar, Kushi, Meyer, Saskia, Kolstad, Arne, Beiske, Klaus, Holte, Harald, Østenstad, Bjørn, Kimby, Eva, Olweus, Johanna, Tasken, Kjetil, Lorenz, Suzanne, Smeland, Erlend B., Alizadeh, Ash A., Huse, Kanutte, and Myklebust, June Helen
- Abstract
Kolstad: Merck: Research Funding; Nordic Nanovector: Membership on an entity's Board of Directors or advisory committees, Research Funding. Alizadeh:Janssen: Consultancy; Genentech: Consultancy; Pharmacyclics: Consultancy; Chugai: Consultancy; Celgene: Consultancy; Gilead: Consultancy; Roche: Consultancy; Pfizer: Research Funding.
- Published
- 2020
- Full Text
- View/download PDF
41. Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden
- Author
-
Weibull, Caroline, Wahlin, Björn E, Lockmer, Sandra, Enblad, Gunilla, Andersson, Per-Ola, Kimby, Eva, and Smedby, Karin E.
- Abstract
Purpose:Follicular lymphoma (FL) is generally regarded as an indolent malignancy, yet the clinical outcome is highly variable. In recent years, POD24 (progression of disease within 24 months) has emerged as a potential prognostic marker for overall survival (OS) in FL and other non-Hodgkin lymphomas. The association with survival, however, has mostly been studied in selected clinical trial cohorts and among patients treated with R-CHOP. We aimed to investigate OS by timing of progression and type of primary treatment in a population-based setting in Sweden.
- Published
- 2020
- Full Text
- View/download PDF
42. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma
- Author
-
Nygren, Lina, Baumgartner Wennerholm, Stefanie, Klimkowska, Monika, Christensson, Birger, Kimby, Eva, and Sander, Birgitta
- Abstract
The prognostic role of the transcription factor SOX11 in mantle cell lymphoma (MCL) is controversial. We investigated prognostic markers in a population-based cohort of 186 MCL cases. Seventeen patients (9%) did not require any therapy within the first 2 years after diagnosis and were retrospectively defined as having an indolent disease. As expected, indolent MCL had less frequent B symptoms and extensive nodal involvement and 88% of these cases expressed SOX11. In our cohort 13 cases (7.5%) lacked nuclear SOX11 at diagnosis. SOX11− MCL had a higher frequency of lymphocytosis, elevated level of lactate dehydrogenase (LDH), and p53 positivity. The overall survival in the whole cohort, excluding 37 patients receiving autologous stem cell transplantation, was 3.1 year and in patients with indolent or nonindolent disease, 5.9 and 2.8 years, respectively (P = .004). SOX11− cases had a shorter overall survival, compared with SOX11+ cases, 1.5 and 3.2 years, respectively (P = .014). In multivariate analysis of overall survival, age > 65 (P = .001), Eastern Cooperative Oncology Group score ≥ 2 (P = .022), elevated LDH level (P = .001), and p53 expression (P = .001) remained significant, and SOX11 lost significance. We conclude that most indolent MCLs are SOX11+ and that SOX11 cannot be used for predicting an indolent disease course.
- Published
- 2012
- Full Text
- View/download PDF
43. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
- Author
-
Geisler, Christian H., Kolstad, Arne, Laurell, Anna, Räty, Riikka, Jerkeman, Mats, Eriksson, Mikael, Nordström, Marie, Kimby, Eva, Boesen, Anne Marie, Nilsson-Ehle, Herman, Kuittinen, Outi, Lauritzsen, Grete F., Ralfkiær, Elisabeth, Ehinger, Mats, Sundström, Christer, Delabie, Jan, Karjalainen-Lindsberg, Marja-Liisa, Brown, Peter, and Elonen, Erkki
- Abstract
Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680.
- Published
- 2010
- Full Text
- View/download PDF
44. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
- Author
-
Geisler, Christian H., Kolstad, Arne, Laurell, Anna, Räty, Riikka, Jerkeman, Mats, Eriksson, Mikael, Nordström, Marie, Kimby, Eva, Boesen, Anne Marie, Nilsson-Ehle, Herman, Kuittinen, Outi, Lauritzsen, Grete F., Ralfkiær, Elisabeth, Ehinger, Mats, Sundström, Christer, Delabie, Jan, Karjalainen-Lindsberg, Marja-Liisa, Brown, Peter, Elonen, Erkki, and Group, for the Nordic Lymphoma
- Abstract
Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P< .001) than the International Prognostic Index (P> .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB(biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIBis feasible. This trial was registered at www.isrctn.orgas #ISRCTN 87866680.
- Published
- 2010
- Full Text
- View/download PDF
45. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
- Author
-
Treon, Steven P., Branagan, Andrew R., Ioakimidis, Leukothea, Soumerai, Jacob D., Patterson, Christopher J., Turnbull, Barry, Wasi, Parveen, Emmanouilides, Christos, Frankel, Stanley R., Lister, Andrew, Morel, Pierre, Matous, Jeffrey, Gregory, Stephanie A., and Kimby, Eva
- Abstract
We report the long-term outcome of a multicenter, prospective study examining fludarabine and rituximab in Waldenström macroglobulinemia (WM). WM patients with less than 2 prior therapies were eligible. Intended therapy consisted of 6 cycles (25 mg/m2 per day for 5 days) of fludarabine and 8 infusions (375 mg/m2 per week) of rituximab. A total of 43 patients were enrolled. Responses were: complete response (n = 2), very good partial response (n = 14), partial response (n = 21), and minor response (n = 4), for overall and major response rates of 95.3% and 86.0%, respectively. Median time to progression for all patients was 51.2 months and was longer for untreated patients (P = .017) and those achieving at least a very good partial response (P = .049). Grade 3 or higher toxicities included neutropenia (n = 27), thrombocytopenia (n = 7), and pneumonia (n = 6), including 2 patients who died of non–Pneumocystis carinii pneumonia. With a median follow-up of 40.3 months, we observed 3 cases of transformation to aggressive lymphoma and 3 cases of myelodysplastic syndrome/acute myeloid leukemia. The results of this study demonstrate that fludarabine and rituximab are highly active in WM, although short- and long-term toxicities need to be carefully weighed against other available treatment options. This study is registered at clinicaltrials.gov as NCT00020800.
- Published
- 2009
- Full Text
- View/download PDF
46. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
- Author
-
Treon, Steven P., Branagan, Andrew R., Ioakimidis, Leukothea, Soumerai, Jacob D., Patterson, Christopher J., Turnbull, Barry, Wasi, Parveen, Emmanouilides, Christos, Frankel, Stanley R., Lister, Andrew, Morel, Pierre, Matous, Jeffrey, Gregory, Stephanie A., and Kimby, Eva
- Abstract
We report the long-term outcome of a multicenter, prospective study examining fludarabine and rituximab in Waldenström macroglobulinemia (WM). WM patients with less than 2 prior therapies were eligible. Intended therapy consisted of 6 cycles (25 mg/m2per day for 5 days) of fludarabine and 8 infusions (375 mg/m2per week) of rituximab. A total of 43 patients were enrolled. Responses were: complete response (n = 2), very good partial response (n = 14), partial response (n = 21), and minor response (n = 4), for overall and major response rates of 95.3% and 86.0%, respectively. Median time to progression for all patients was 51.2 months and was longer for untreated patients (P= .017) and those achieving at least a very good partial response (P= .049). Grade 3 or higher toxicities included neutropenia (n = 27), thrombocytopenia (n = 7), and pneumonia (n = 6), including 2 patients who died of non–Pneumocystis cariniipneumonia. With a median follow-up of 40.3 months, we observed 3 cases of transformation to aggressive lymphoma and 3 cases of myelodysplastic syndrome/acute myeloid leukemia. The results of this study demonstrate that fludarabine and rituximab are highly active in WM, although short- and long-term toxicities need to be carefully weighed against other available treatment options. This study is registered at clinicaltrials.gov as NCT00020800.
- Published
- 2009
- Full Text
- View/download PDF
47. Advances in the Biology and Treatment of Waldenström's Macroglobulinemia: A Report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden
- Author
-
Treon, Steven P., Patterson, Christopher J., Kimby, Eva, and Stone, Marvin J.
- Published
- 2009
- Full Text
- View/download PDF
48. TCL1Aexpression delineates biological and clinical variability in B-cell lymphoma
- Author
-
Aggarwal, Mohit, Villuendas, Raquel, Gomez, Gonzalo, Rodriguez-Pinilla, Socorro M, Sanchez-Beato, Margarita, Alvarez, David, Martinez, Nerea, Rodriguez, Antonia, Castillo, Maria E, Camacho, Francisca I, Montes-Moreno, Santiago, Garcia-Marco, Jose A, Kimby, Eva, Pisano, David G, and Piris, Miguel A
- Abstract
The assembly of a collection of gene-expression signatures of the major types of B-cell non-Hodgkin's lymphoma has identified increased T-cell leukemia/lymphoma 1A (TCL1) expression in multiple lymphoma types and cases, and has enabled the investigation of the functional and clinical importance of TCL1 expression. Specifically, Burkitt's lymphoma cases show a homogeneously strong expression of TCL1, whereas diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, nodal marginal zone lymphoma, and splenic marginal zone lymphoma display a striking variability in the intensity of TCL1 staining. This was validated in two independent series. A Gene-Set Enrichment Analysis of the genes correlated with TCL1Aexpression found that variation in the level of expression of TCL1Awas significantly associated with some of the most important gene signatures recognizing B-cell lymphoma pathogenesis and heterogeneity, such as germinal center, B-cell receptor, NF-κB (and its target genes), death, MAP kinases, TNFR1, TOLL, and IL1R. Additionally, TCL1 expression was correlated with shorter time to treatment in chronic lymphocytic leukemia cases and shorter lymphoma-specific survival in mantle cell lymphoma series, thus indicating the clinical and biological significance of TCL1 expression, and suggesting TCL1A as a potential therapeutic target.
- Published
- 2009
- Full Text
- View/download PDF
49. Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma
- Author
-
Spasevska, Ivana, Sharma, Ankush, Steen, Chloe B., Josefsson, Sarah, Blaker, Yngvild Nuvin, Rustad, Even H, Meyer, Saskia, Chellappa, Stalin, Kushekhar, Kushi, Kolstad, Arne, Beiske, Klaus, Holte, Harald, Østenstad, Bjørn, Kimby, Eva, Olweus, Johanna, Tasken, Kjetil, Lorenz, Suzanne, Smeland, Erlend B., Alizadeh, Ash A., Huse, Kanutte, and Myklebust, June Helen
- Abstract
Introduction:Regulatory T cells (Tregs), a highly immunosuppressive subset of CD4 +T cells, represent a key challenge in the tumor microenvironment by limiting potent antitumor immune responses. While high densities of tumor-infiltrating Tregs are associated with poor prognosis in patients with various types of solid cancers, their prognostic impact in B-cell non-Hodgkin lymphoma (NHL) remains unclear. Emerging studies suggest substantial heterogeneity in the phenotype and suppressive capacities of Tregs, emphasizing the importance of understanding Treg diversity and the need for additional markers to identify highly suppressive Tregs. Our in-depth characterization of Tregs in NHL tumors could open new paths for rational drug design, facilitating selective therapeutic manipulation of Tregs to reduce immunosuppression and improve anti-tumor immunity.
- Published
- 2021
- Full Text
- View/download PDF
50. Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma
- Author
-
Spasevska, Ivana, Sharma, Ankush, Steen, Chloe B., Josefsson, Sarah, Blaker, Yngvild Nuvin, Rustad, Even H, Meyer, Saskia, Chellappa, Stalin, Kushekhar, Kushi, Kolstad, Arne, Beiske, Klaus, Holte, Harald, Østenstad, Bjørn, Kimby, Eva, Olweus, Johanna, Tasken, Kjetil, Lorenz, Suzanne, Smeland, Erlend B., Alizadeh, Ash A., Huse, Kanutte, and Myklebust, June Helen
- Abstract
Holte: Gilead: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Nordic: Membership on an entity's Board of Directors or advisory committees; Nanovector: Membership on an entity's Board of Directors or advisory committees, Other: lectures honorarias; Novartis: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees. Alizadeh: Cibermed: Consultancy, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company; CAPP Medical: Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company; Forty Seven: Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company; Foresight Diagnostics: Consultancy, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company; Roche: Consultancy, Honoraria; Janssen Oncology: Honoraria; Celgene: Consultancy, Research Funding; Gilead: Consultancy; Bristol Myers Squibb: Research Funding.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.